Karyopharm Therapeutics Stock (NASDAQ: KPTI) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 3.000 / 1.769M |
Day Range | - - - |
52 Wk Range | 0.617 - 4.110 |
Market Cap | $126.948M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 41 |
Short Interest | 20.12% |
Days to Cover | 25.3 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Karyopharm Therapeutics (NASDAQ: KPTI) through any online brokerage.
Other companies in Karyopharm Therapeutics’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), CytomX Therapeutics (NASDAQ:CTMX), Vistagen Therapeutics (NASDAQ:VTGN), GlycoMimetics (NASDAQ:GLYC) and Adagene (NASDAQ:ADAG).
The latest price target for Karyopharm Therapeutics (NASDAQ: KPTI) was reported by HC Wainwright & Co. on Friday, March 1, 2024. The analyst firm set a price target for 8.00 expecting KPTI to rise to within 12 months (a possible 633.94% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Karyopharm Therapeutics (NASDAQ: KPTI) is $1.09 last updated April 24, 2024 at 7:06 PM EDT.
There are no upcoming dividends for Karyopharm Therapeutics.
Karyopharm Therapeutics’s Q1 earnings are confirmed for Monday, May 6, 2024.
There is no upcoming split for Karyopharm Therapeutics.
Karyopharm Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.